Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | EBP | Q15125 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CDC25A | P30304 | 1/20 | 0.30 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1658320 | 0.94 | LMNA (0.48) | LMNABLMCA1PTPN1MEN1 | |
| SCHEMBL20530409 | 0.92 | LMNA (0.62) | LMNABLMCA1PTPN1MEN1 | |
| SCHEMBL2555075 | 0.92 | LMNA (0.62) | LMNABLMCA1PTPN1MEN1 | |
| SCHEMBL2696106 | 0.82 | LMNA (0.48) | LMNABLMCA1PTPN1MEN1 | |
| SCHEMBL15722824 | 0.82 | TSHR (0.35) | TRPV1TRPA1TSHR | |
| SCHEMBL1657177 | 0.81 | CA1 (0.39) | LMNACA1TSHR | |
| SCHEMBL15160302 | 0.78 | LMNA (0.43) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL28474503 | 0.78 | LMNA (0.50) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL42290 | 0.77 | — | — | |
| SCHEMBL16469538 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6844302-B1 | Encapsulated flavor and fragrance | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2005-01-18 | — | — | US | claimed |
| US-20240410055-A1 | METHOD AND FORMULATION FOR PREPARING OPTICAL METAL OXIDE LAYERS | MERCK PATENT GMBH (DE) | 2024-12-12 | — | — | US | disclosed |
| CN-118076767-A | Method and formulation for producing an optical metal oxide layer | 默克专利有限公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2023057401-A1 | METHOD AND FORMULATION FOR PREPARING OPTICAL METAL OXIDE LAYERS | MERCK PATENT GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| CN-105308162-B | Compounds for the controlled release of active molecules | 弗门尼舍有限公司 | 2022-10-11 | — | — | CN | disclosed |
| EP-3180311-B1 | METHOD FOR PRODUCING ASTAXANTHIN FROM ASTACIN | BASF SE (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-10017464-B2 | Process for preparing cyclic alpha-keto alcohols from cyclic alpha-keto enols | BASF SE (DE) | 2018-07-10 | — | — | US | disclosed |
| US-10017465-B2 | Method for producing astaxanthin from astacin | BASF SE (DE) | 2018-07-10 | — | — | US | disclosed |
| US-20170233338-A1 | METHOD FOR PRODUCING ASTAXANTHIN FROM ASTACIN | BASF SE (DE) | 2017-08-17 | — | — | US | disclosed |
| US-20170217884-A1 | PROCESS FOR PREPARING CYCLIC ALPHA-KETO ALCOHOLS FROM CYCLIC ALPHA-KETO ENOLS | BASF SE (DE) | 2017-08-03 | — | — | US | disclosed |
| US-8632792-B2 | Cooling sensation agent composition and sensory stimulation agent composition | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-01-21 | — | — | US | disclosed |
| US-20130157857-A1 | INHIBITOR FOR TOBACCO AXILLARY BUD GROWTH AND METHOD FOR INHIBITING TOBACCO AXILLARY BUD GROWTH | SDS BIOTECH K.K. (JP) | 2013-06-20 | — | — | US | disclosed |
| US-20130131169-A1 | COOLING SENSATION AGENT COMPOSITION, SENSORY STIMULATION AGENT COMPOSITION AND USE OF THE SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-05-23 | — | — | US | disclosed |
| CN-103096709-A | Inhibitor for tobacco axillary bud growth and method for inhibiting tobacco axillary bud growth | SDS BIOTECH CORP | 2013-05-08 | — | — | CN | disclosed |
| US-8377458-B2 | Cooling sensation agent composition, sensory stimulation agent composition and use of the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20110117147-A1 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110081393-A1 | COOLING SENSATION AGENT COMPOSITION, SENSORY STIMULATION AGENT COMPOSITION AND USE OF THE SAME | TAKASAGO INTERNATIONAL CORPORATION | 2011-04-07 | — | — | US | disclosed |
| WO-2009123355-A2 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-10-08 | — | — | WO | disclosed |
| US-5554588-A | IN WHICH AT LEAST HALF COMPRISES ETHERS, AROMATIC METHYL KETONES, ALCOHOLS, ESTERS AND SALICYLATES; DEODORANTS AND ACCEPTABLE FRAGRANCE | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1996-09-10 | — | — | US | disclosed |
| US-4021461-A | INSECTICIDES | ZOECON CORPORATION (US) | 1977-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233338-A1 | METHOD FOR PRODUCING ASTAXANTHIN FROM ASTACIN | ADH1B, ADH5, ADH7 | LMNA 2917/4885BLM 1141/4885CA1 987/4885 |
| US-20110117147-A1 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TRPA1, HRH1, HRH2 | LMNA 1708/4885BLM 4418/4885CA1 3505/4885 |
| US-10017465-B2 | Method for producing astaxanthin from astacin | ADH1B, ADH5, ADH7 | LMNA 2917/4885BLM 1141/4885CA1 987/4885 |
| US-20170217884-A1 | PROCESS FOR PREPARING CYCLIC ALPHA-KETO ALCOHOLS FROM CYCLIC ALPHA-KETO ENOLS | AKR1C3, AKR1C2, AKR1A1 | LMNA 1180/4885BLM 2489/4885CA1 1211/4885 |
| US-10017464-B2 | Process for preparing cyclic alpha-keto alcohols from cyclic alpha-keto enols | AKR1C3, AKR1C2, AKR1A1 | LMNA 1180/4885BLM 2489/4885CA1 1211/4885 |
| US-20110081393-A1 | COOLING SENSATION AGENT COMPOSITION, SENSORY STIMULATION AGENT COMPOSITION AND USE OF THE SAME | TRPA1, TRPV1, TRPM4 | LMNA 1727/4885BLM 4563/4885CA1 1310/4885 |
| US-20130131169-A1 | COOLING SENSATION AGENT COMPOSITION, SENSORY STIMULATION AGENT COMPOSITION AND USE OF THE SAME | TRPA1, TRPV1, TRPM4 | LMNA 1727/4885BLM 4563/4885CA1 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.